Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 20, 2009

FDA Says Erbitux No Good for Those with Certain K-ras Mutations

  • FDA has made changes to the U.S. prescribing information for Erbitux with regards to treating those with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). The label states that the drug is not recommended for patients whose tumors have K-ras mutations in codon 12 or 13.

    FDA’s revisions included a statement that retrospective subset analyses of metastatic or advanced colorectal cancer trials did not show a treatment benefit for Erbitux in patients whose tumors had these K-ras mutations. These modifications were also made to the clinical studies and clinical pharmacology sections of the product’s prescribing information.

    About 40% of patients with mCRC have K-ras mutations, according to ImClone and Bristol-Myers Squibb, the companies that market Erbitux. Signal transduction through the EGFR results in activation of wild-type K-ras protein. In cells with activating K-ras somatic mutations, however, the mutant K-ras protein is continuously active and appears independent of EGFR regulation.

    In mCRC Erbitux is approved by the FDA as: a single agent for EGFR-expressing mCRC after failure of both irinotecan- and oxaliplatin-based regimens; a single agent for EGFR-expressing mCRC in patients who are intolerant to irinotecan-based regimens; and in combination with irinotecan for the treatment of EGFR-expressing mCRC in patients who are refractory to irinotecan-based chemotherapy.



Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »